Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Member News > New Surgical Facilities Set to Reduce Waiting Times for Kiwi Skin Cancer Patients

New Surgical Facilities Set to Reduce Waiting Times for Kiwi Skin Cancer Patients

Kiwis living with skin cancer are set to benefit with the launch of new dedicated surgical facilities capable of treating thousands of patients around New Zealand each year.
8 Aug 2022
Written by Kirsten Harris
Member News
Michelle Aquilina, MoleMap CEO
Michelle Aquilina, MoleMap CEO

Kiwis living with skin cancer are set to benefit with the launch of new dedicated surgical facilities capable of treating thousands of patients around New Zealand each year.

The move is expected to increase specialised skin cancer surgical capacity within the healthcare sector as well as reducing the time between diagnosis and treatment for newly diagnosed cancer patients.

Skin cancer, including non-melanoma and the more deadly melanoma, is New Zealand's most common cancer with an estimated 90,000 non-melanoma skin lesions diagnosed each year.[1]

New Zealand also has the world's highest rates of melanoma with 4,000 new cases and over 350 Kiwis dying from this form of cancer every year.[2]

The national cost of treating skin cancer is set to reach $295 million within three years.[3]

The country's largest skin cancer detection service, MoleMap, will launch new surgical facilities in their network of clinics which will see thousands of Kiwis with cancerous skin lesions provided with immediate surgical treatments following their diagnosis.

MoleMap, which has over 300,000 patients across New Zealand and Australia and is set to significantly increase in size over the next three years has plans to double in size over the next three years - providing new skin cancer treatment options on both sides of the Tasman.

To provide greater support for the mental health of patients and their whanau, the company will also offer counselling services for those diagnosed with skin cancer.

An advanced training programme will also upskill its international network of melanographers who are qualified registered nurses to provide non-surgical treatment options at the point of diagnosis - for a range of precancerous skin lesions.

Dr Franz Strydom, MoleMap chief medical officer New Zealand, says melanoma can be cured in 98% of cases if diagnosed early. 

He says when diagnosed at a later stage, melanoma becomes more difficult and expensive to treat with a greater chance of treatment failure . 

“Unlike most other forms of cancer, the development of melanoma can often be identified and tracked on the surface of the skin - providing the opportunity to excise it before it spreads to other parts of the body .

“As a result, early detection would more likely result in early treatment and a positive outcome.

“The new health care model developed by MoleMap is designed to allow expedited and empathetic treatment for this patient cohort,” he says.

Dr Strydom says while New Zealand has the world's highest melanoma mortality rates, very few general practitioners specialise in assessing and treating skin cancer.

Michelle Aquilina, MoleMap CEO, says the strategic expansion programme is a significant milestone as it marks the evolution of a Kiwi medtech startup into a fully integrated, international health care provider.

She says the company has developed a new treatment model which will allow them to provide the surgical capacity that can be rapidly scaled up to meet patient demand.

“For over a quarter of a century, MoleMap has been at the forefront of skin cancer diagnosis in countries with high mortality rates of the disease.

“That experience has shown us that a patient-centric healthcare model is essential to widening access to specialist treatment and improving outcomes for those with this form of cancer.

“By integrating detection and treatment, we can extend our service from ongoing surveillance and teledermatology diagnosis through to treatment - effectively closing the loop on skin cancer prevention and streamlining the patient journey,” she says.

Aquilina says the first stage of the expansion strategy will see the strategic growth programme bring up to seven Australiasian dermatology and GP led clinics specialising in the treatment of skin cancer into the MoleMap group each year.

She says doctors will operate in centres around the country to provide surgical procedures to patients - providing resource flexibility in urban and rural centres around New Zealand, closely followed by Australia.

“The first of the specialised skin clinics to be brought into the MoleMap group will be the Bay of Plenty practice Skinspots - which is made up of a team of 18 doctors, nurses and support staff.

“The HCPs from the clinic will form part of our 'hub and spoke' model where skin cancer treatment is extended beyond the region into satellite clinics - which are part of our existing network.

“We will also look to recruit other GPs and dermatologists from around the country who have experience and expertise in treating skin cancer and connect them with a large number of patients referred from our diagnostic services.

“This model will allow doctors to concentrate on patient care - while we take care of the administration,” she says.

-Ends-

Written on behalf of MoleMap, by Impact PR. For more information or images, please contact Mark Devlin mark@impactpr.co.nz

[1] Gordon L. et al. (2022). Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021. Int J Environ Res Public Health, 19(6). Accessible here.

[2] Environmental Health Intelligence NZ. Accessible here.

[3] Gordon L. et al. (2022). Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021. Int J Environ Res Public Health, 19(6). Accessible here.

Similar stories

Share your news!

 

Copyright © 2022
Digital Health Association
NZ Incorporated

This website is powered by
ToucanTech